DSSG Group: Paediatric

The EBMT Registry contains patient clinical data, including aspects of the diagnosis and disease, first-line treatments, HCT or cell-therapy-associated procedures, transplant type, donor type, stem cell source, complications and outcome. Patients are followed up indefinitely.

The international, multicenter registry LOGGIC Core BioClinical Data Bank aims to enhance the understanding of tumor biology in pediatric low-grade glioma (pLGG) and provide clinical and molecular data to support treatment decisions and interventional trial participation.

Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.

Children suffering from Diffuse Intrinsic Pontine Glioma (“DIPG”

To find effective treatments for DIPG and DMG, researchers need to better understand how the diseases work. Because DIPGs and DMGs are rare compared to adult brain tumors, most hospitals see few patients with these tumors, making it difficult for researchers to collect enough information to look for new treatments. And because most DIPGs are not biopsied, researchers do not have access to large numbers of tumor samples for research. The DIPG/DMG Registry will collect information and tumor samples from DIPG and DMG patients around the world and make it available to researchers studying the disease.

Children, adolescents and young adults with ependymoma

Test

Neuroblastoma

Targeting metabolism to improve NK cell mediated Immunotherapy for the treatment of Neuroblastoma

Langerhans cell histiocytosis

International Collaborative Treatment Protocol for Children and Adolescents with LCH.

Paediatric patients with Chronic Myeloid Leukemia.

To establish the efficacy, safety, and tolerability of bosutinib.

CD22-positive acute lymphocytic leukemia (ALL)